PLI Schemes — Combined Key Metrics
Across 3 schemes
Bulk Drugs + Pharmaceuticals
Pharma + Bulk Drugs
Pharma + Bulk Drugs
Across pharma & bulk drugs
APIs, KSMs & DIs covered
Unique product categories
Bulk Drugs + Pharma
Overview
India's Production Linked Incentive (PLI) schemes for Bulk Drugs, Pharmaceuticals and Medical Devices are creating a broader manufacturing framework that spans critical inputs, APIs, high-value medicines and advanced medical devices. The three schemes together aim to strengthen domestic manufacturing capacity, reduce import dependence and support technology adoption across the pharmaceutical value chain.
As of June 2026, the schemes have collectively generated substantial investment, sales, exports and employment. The pharmaceutical PLI scheme alone has attracted actual investment of ₹46,744 crore, significantly exceeding its ₹17,275 crore target, while cumulative sales have reached ₹4.03 lakh crore.
PLI Scheme for Bulk Drugs
Approved in 2020 with a financial outlay of ₹6,940 crore, the PLI Scheme for Bulk Drugs was designed to strengthen domestic manufacturing of 41 critical products, including Active Pharmaceutical Ingredients (APIs), Key Starting Materials (KSMs) and Drug Intermediates (DIs).
Progress as of June 2026
- 48 projects approved under the scheme
- Investment of ₹5,210.74 crore recorded
- Exceeded committed investment of ₹4,330 crore
- 39 projects covering 28 APIs and KSMs commissioned
- Around 5,127 people employed
Sales, Exports & Products
- Beneficiaries generated sales of ₹3,792.49 crore
- Exports amounted to ₹560.16 crore
- Supported fermentation-based Penicillin-G production
- Supported Clavulanic Acid domestic manufacturing
- Supported Rifampicin production capabilities
PLI Scheme for Pharmaceuticals
The PLI Scheme for Pharmaceuticals, approved in 2021 with an outlay of ₹15,000 crore, focuses on higher-value pharmaceutical manufacturing. Supported product categories include biopharmaceuticals, complex generics, patented and off-patent drugs, orphan drugs, auto-immune medicines and other high-value pharmaceutical products.
Participation & Investment
- 55 applicants selected, including 20 MSMEs
- Actual investment reached ₹46,744 crore
- Compared with a target of ₹17,275 crore
- Employment generated reached 1,21,294 jobs
- Investment significantly exceeded scheme target
Sales & Exports Performance
- Cumulative sales reached ₹4.03 lakh crore
- Exports reached ₹2.57 lakh crore
- Supports biopharmaceuticals & complex generics
- Covers patented, off-patent & orphan drugs
- Focus on high-value pharmaceutical products
PLI Scheme for Medical Devices
The PLI Scheme for Medical Devices, approved in 2020 with an outlay of ₹3,420 crore, is supporting domestic manufacturing of advanced medical technologies. The scheme has supported production of 57 unique medical devices, spanning diagnostic imaging, surgical and life-saving equipment categories.
MRI Machines
Domestic manufacturing of Magnetic Resonance Imaging systems for diagnostic use.
CT Scanners
Advanced Computed Tomography imaging equipment for medical diagnostics.
Cath Labs
Cardiac Catheterization Laboratories for interventional cardiology procedures.
Linear Accelerators
High-energy radiation therapy systems used for cancer treatment.
C-Arms & Mammography
Mobile imaging systems and mammography machines for surgical and screening use.
Ultrasound Systems
Diagnostic ultrasound imaging equipment for a wide range of clinical applications.
Anaesthesia Machines
Life-support equipment for surgical and critical-care anaesthesia delivery.
Heart Valves
Advanced cardiac implants used in valve-replacement surgical procedures.
Advanced Med-Tech
Broader domestic capability across sophisticated diagnostic and medical technologies.
Why This Matters
India's pharmaceutical ecosystem depends not only on finished medicines but also on APIs, KSMs, intermediates and advanced manufacturing technologies. Strengthening these upstream and high-value segments is essential for supply-chain resilience and long-term competitiveness.
The three PLI programmes address multiple layers of the value chain—from critical pharmaceutical inputs to high-value medicines and medical devices. The reported investment, sales, exports and employment figures indicate the scale of activity generated under the schemes as of June 2026 and highlight India's shift toward deeper domestic manufacturing capabilities.
💡 FinIntelHub Insight
Building a Full-Stack Pharmaceutical Manufacturing Base
India's pharmaceutical manufacturing strategy is increasingly focused on moving beyond finished-drug production toward deeper domestic capabilities across the value chain. The combination of bulk-drug, pharmaceutical and medical-device PLI schemes creates a broader manufacturing framework covering critical inputs → APIs → high-value medicines → advanced medical devices.
For FinIntelHub's Pharmaceuticals sector coverage, these schemes are important indicators for tracking domestic manufacturing capacity, investment mobilisation, exports, import dependence and technology adoption. The scale of activity under the pharmaceutical PLI, in particular—where actual investment has significantly exceeded the target and cumulative sales have crossed ₹4 lakh crore—signals a structural strengthening of India's position across the global pharmaceutical value chain.
Source: Information provided in the source text; figures stated as of June 2026.
Disclaimer: FinIntelHub is not responsible for any errors or omissions in the information presented. The data and information are compiled from secondary sources and are provided for informational and research purposes only.